Topical insulin in neurotrophic keratopathy after diabetic vitrectomy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 05 2024
Historique:
received: 29 12 2023
accepted: 26 04 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 14 5 2024
Statut: epublish

Résumé

To assess the efficacy and safety of topical insulin (TI) for treating neurotrophic keratopathy (NK) within one-month post-diabetic vitrectomy (DV) compared to conventional non-invasive measures, we conducted this retrospective case-control study including all eyes that developed acute NK (stages 2 and 3) following DV between October 2020 and June 2023. The control group included NK cases managed with preservative-free lubricant eye drops and prophylactic topical antibiotics. In contrast, the study group included NK cases treated with TI [1 unit per drop] four times daily, in addition to the previously mentioned treatment. The primary outcome measure was time to epithelial healing. Secondary outcome measures included any adverse effect of TI or the need for amniotic membrane transplantation (AMT). During the study period, 19 patients with a mean age of 49.3 ± 8.6 years received TI versus 18 controls with a mean age of 52.5 ± 10.7 years. Corneal epithelial healing was significantly faster in the TI-treated group compared to controls, with a mean difference of 12.16 days (95% CI 6.1-18.3, P = 0.001). Survival analysis indicated that the insulin-treated group had 0% and 20% of NK stages 2 and 3, respectively, that failed to achieve corneal epithelial healing, compared to 20% and 66.7% for the control group (P < 0.001). In the control group, two eyes required AMT due to progressive thinning. Additionally, three patients in the control group, progressing to stage 3 NK, were switched to TI, achieving healing after a mean of 14 days. No adverse effects were reported in the TI-treated group. Our study suggests that TI can effectively and safely promote the healing of NK after DV.

Identifiants

pubmed: 38744994
doi: 10.1038/s41598-024-60699-y
pii: 10.1038/s41598-024-60699-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10986

Informations de copyright

© 2024. The Author(s).

Références

Mastropasqua, L., Massaro-Giordano, G., Nubile, M. & Sacchetti, M. Understanding the pathogenesis of neurotrophic keratitis: The role of corneal nerves. J. Cell. Physiol. 232(4), 717–724. https://doi.org/10.1002/jcp.25623 (2017).
doi: 10.1002/jcp.25623 pubmed: 27683068
Sacchetti, M. & Lambiase, A. Neurotrophic factors and corneal nerve regeneration. Neural Regen. Res. 12(8), 1220 (2017).
doi: 10.4103/1673-5374.213534 pubmed: 28966630 pmcid: 5607810
Sigelman, S. & Friedenwald, J. S. Mitotic and wound-healing activities of the corneal epithelium: Effect of sensory denervotion. AMA Arch. Ophthalmol. 52(1), 46–57 (1954).
doi: 10.1001/archopht.1954.00920050048005 pubmed: 13170864
Chang, B. H. Neurotrophic keratitis. Cornea. 2010, 1101–1109 (2010).
Hsu, H. Y. & Modi, D. Etiologies, quantitative hypoesthesia, and clinical outcomes of neurotrophic keratopathy. Eye Contact Lens 41(5), 314–317 (2015).
doi: 10.1097/ICL.0000000000000133 pubmed: 25828513
Saad, S. et al. Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes. Ocular Surf. 18(2), 231–236. https://doi.org/10.1016/j.jtos.2019.11.008 (2020).
doi: 10.1016/j.jtos.2019.11.008
Priyadarsini, S. et al. Diabetic keratopathy: Insights and challenges. Surv. Ophthalmol. 65(5), 513–529 (2020).
doi: 10.1016/j.survophthal.2020.02.005 pubmed: 32092364 pmcid: 8116932
Israilevich, R. N. et al. Neurotrophic keratopathy following rhegmatogenous retinal detachment surgery. Can. J. Ophthalmol. https://doi.org/10.1016/j.jcjo.2023.05.015 (2023).
doi: 10.1016/j.jcjo.2023.05.015 pubmed: 37330215
Kurt, R. A., Sonmez, B. & Kapran, Z. Neurotrophic keratopathy after retinal detachment surgery combined with endolaser photocoagulation. Retin. Cases Brief Rep. 15(4), 479–481. https://doi.org/10.1097/icb.0000000000000832 (2021).
doi: 10.1097/icb.0000000000000832 pubmed: 30300314
Menchini, U., Scialdone, A., Pietroni, C., Carones, F. & Brancato, R. Argon versus krypton panretinal photocoagulation side effects on the anterior segment. Ophthalmologica. 201(2), 66–70. https://doi.org/10.1159/000310129 (1990).
doi: 10.1159/000310129 pubmed: 2234817
Perez, C. I., Han, Y., Rose-Nussbaumer, J., Ou, Y. & Hsia, Y. C. Neurotrophic keratitis after micropulse transscleral diode laser cyclophotocoagulation. Am. J. Ophthalmol. Case Rep. 15, 100469. https://doi.org/10.1016/j.ajoc.2019.100469 (2019).
doi: 10.1016/j.ajoc.2019.100469 pubmed: 31193794 pmcid: 6543013
Sayed, M. S., Khodeiry, M. M., Elhusseiny, A. M., Sabater, A. L. & Lee, R. K. Neurotrophic keratopathy after slow coagulation transscleral cyclophotocoagulation. Cornea. https://doi.org/10.1097/ico.0000000000003325 (2023).
doi: 10.1097/ico.0000000000003325 pubmed: 37535806
Wolff, E. & Warwick, R. Eugene Wolff’s Anatomy of the Eye and Orbit: Including the Central Connexions, Development, and Comparative Anatomy of the Visual Apparatus (Springer, 1976).
Margolis, T. P. Neurotrophic keratopathy: Ophthalmology’s diabetic foot problem. Eye Contact Lens. 47(3), 136–139 (2021).
doi: 10.1097/ICL.0000000000000774 pubmed: 33599469
Lockwood, A., Hope-Ross, M. & Chell, P. Neurotrophic keratopathy and diabetes mellitus. Eye. 20(7), 837–839 (2006).
doi: 10.1038/sj.eye.6702053 pubmed: 16215544
Roumeau, S. et al. Efficacy of treatments for neurotrophic keratopathy: A systematic review and meta-analysis. Graefe’s Arch. Clin. Exp. Ophthalmol. 260(8), 2623–2637 (2022).
Liu, C. Y. et al. Corneal neurotization for neurotrophic keratopathy: Review of surgical techniques and outcomes. Ocular Surf. 20, 163–172. https://doi.org/10.1016/j.jtos.2021.02.010 (2021).
doi: 10.1016/j.jtos.2021.02.010
Elhusseiny, A. M., Traish, A. S., Saeed, H. N. & Mantagos, I. S. Topical cenegermin 0.002% for pediatric neurotrophic keratopathy. Eur. J. Ophthalmol. 32(6), 3420–3424. https://doi.org/10.1177/11206721221094783 (2022).
doi: 10.1177/11206721221094783 pubmed: 35469461
Solyman, O., Elhusseiny, A. M., Ali, S. F. & Allen, R. A review of pediatric corneal neurotization. Int. Ophthalmol. Clin. 62(1), 83–94. https://doi.org/10.1097/iio.0000000000000403 (2022).
doi: 10.1097/iio.0000000000000403 pubmed: 34965228
Aynsley, T. The use of insulin in the treatment of corneal ulcers. Br. J. Ophthalmol. 29(7), 361 (1945).
doi: 10.1136/bjo.29.7.361 pubmed: 18170130 pmcid: 513802
Fai, S., Ahem, A., Mustapha, M., Noh, U. K. M. & Bastion, M.-L.C. Randomized controlled trial of topical insulin for healing corneal epithelial defects induced during vitreoretinal surgery in diabetics. Asia-Pac. J. Ophthalmol. 6(5), 418–424 (2017).
Wang, A. L. et al. The use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea. 36(11), 1426 (2017).
doi: 10.1097/ICO.0000000000001297 pubmed: 28742619 pmcid: 5633504
Galvis, V., Niño, C., Tello, A., Grice, J. & Gómez, M. Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma. Arch. Soc. Española Oftalmol. (English Edition). 94(2), 100–104 (2019).
doi: 10.1016/j.oftale.2018.06.012
Serrano-Giménez, R., Contreras-Macías, E., García-Bernal, A. & Fobelo-Lozano, M. J. Insulin eye drops for treating corneal ulcer in a non-diabetic patient: Regarding a case. Farm. Hosp. 44(6), 297–299 (2020).
pubmed: 33156748
Diaz-Valle, D. et al. Topical insulin for refractory persistent corneal epithelial defects. Eur. J. Ophthalmol. 31(5), 2280–2286 (2021).
doi: 10.1177/1120672120958307 pubmed: 32951459
Soares, R. M., Arêde, C., Fernandes, J., Ferreira, C. & Sequeira, J. Topical Insulin-Utility and results in refractory neurotrophic keratopathy in stages 2 and 3. Investig. Ophthalmol. Vis. Sci. 62(8), 936–936 (2021).
Diaz-Valle, D. et al. Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea. Acta Ophthalmol. 100(4), e912–e919 (2022).
doi: 10.1111/aos.14997 pubmed: 34407296
Machado, S. R. et al. Topical insulin: Utility and results in refractory neurotrophic keratopathy in stages 2 and 3. Cornea. 41(8), 990–994 (2022).
doi: 10.1097/ICO.0000000000002858
Romano, D., Tiew, S. J. & Mohammad, T. P-13 Topical insulin eye drops in infective keratitis. BMJ Spec. J. 1, 1–10 (2023).
Mackie, I., Fraunfelder, F. & Roy, F. Current Ocular Therapy 4th edn, 506–508 (WB Saunders, 1995).
Bastion, M. L. & Ling, K. P. Topical insulin for healing of diabetic epithelial defects? A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients. Med. J. Malay. 68(3), 208–216 (2013).
Esmail, A., Ibrahim, M. & Nage, S. Efficacy of topical insulin for recurrent epithelial corneal erosions. Ir. J. Med. Sci. https://doi.org/10.1007/s11845-023-03373-y (2023).
doi: 10.1007/s11845-023-03373-y pubmed: 37140764
Cruz-Cazarim, E. L. C. et al. Prospective insulin-based ophthalmic delivery systems for the treatment of dry eye syndrome and corneal injuries. Eur. J. Pharm. Biopharm. 140, 1–10. https://doi.org/10.1016/j.ejpb.2019.04.014 (2019).
doi: 10.1016/j.ejpb.2019.04.014 pubmed: 31015020
Aniah Azmi, N. & Bastion, M. C. Short-term results of trial of topical insulin for treatment of dry eyes in diabetics. Eye Contact Lens. 46(Suppl 1), S25-s32. https://doi.org/10.1097/icl.0000000000000623 (2020).
doi: 10.1097/icl.0000000000000623 pubmed: 31145207
Leong, C. Y., Naffi, A. A., Wan Abdul Halim, W. H. & Bastion, M. C. Usage of topical insulin for the treatment of diabetic keratopathy, including corneal epithelial defects. World J. Diabetes. 14(6), 930–938. https://doi.org/10.4239/wjd.v14.i6.930 (2023).
doi: 10.4239/wjd.v14.i6.930 pubmed: 37383598 pmcid: 10294054
Banerjee, P. J., Chandra, A., Sullivan, P. M. & Charteris, D. G. Neurotrophic corneal ulceration after retinal detachment surgery with retinectomy and endolaser: A case series. JAMA Ophthalmol. 132(6), 750–752. https://doi.org/10.1001/jamaophthalmol.2014.280 (2014).
doi: 10.1001/jamaophthalmol.2014.280 pubmed: 24743924
Wang, A. L. et al. Use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea. 36(11), 1426–1428. https://doi.org/10.1097/ico.0000000000001297 (2017).
doi: 10.1097/ico.0000000000001297 pubmed: 28742619 pmcid: 5633504
AuchèreLavayssiere, C., Lux, A. L., Degoumois, A., Stchepinsky Launay, M. & Denion, E. Neurotrophic keratitis after vitrectomy and circumferential endophotocoagulation for retinal detachment. J. Fr. Ophtalmol. 39(2), 195–201. https://doi.org/10.1016/j.jfo.2015.06.008 (2016).
doi: 10.1016/j.jfo.2015.06.008
Fernández-Vega González, Á., Barraquer Compte, R. I., Cárcamo Martínez, A. L., Torrico Delgadillo, M. & de la Paz, M. F. Neurotrophic keratitis after transscleral diode laser cyclophotocoagulation. Arch. Soc. Esp. Oftalmol. 91(7), 320–326. https://doi.org/10.1016/j.oftal.2015.12.001 (2016).
doi: 10.1016/j.oftal.2015.12.001 pubmed: 26810961
Sacchetti, M. & Lambiase, A. Diagnosis and management of neurotrophic keratitis. Clin. Ophthalmol. 8, 571–579. https://doi.org/10.2147/opth.S45921 (2014).
doi: 10.2147/opth.S45921 pubmed: 24672223 pmcid: 3964170
Dua, H. S. et al. Neurotrophic keratopathy. Prog. Retin Eye Res. 66, 107–131. https://doi.org/10.1016/j.preteyeres.2018.04.003 (2018).
doi: 10.1016/j.preteyeres.2018.04.003 pubmed: 29698813
Zagon, I. S., Klocek, M. S., Sassani, J. W. & McLaughlin, P. J. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch. Ophthalmol. 125(8), 1082–1088. https://doi.org/10.1001/archopht.125.8.1082 (2007).
doi: 10.1001/archopht.125.8.1082 pubmed: 17698755
Song, F. et al. Insulin restores an altered corneal epithelium circadian rhythm in mice with streptozotocin-induced type 1 diabetes. Sci. Rep. 6, 32871. https://doi.org/10.1038/srep32871 (2016).
doi: 10.1038/srep32871 pubmed: 27611469 pmcid: 5017193
Titone, R., Zhu, M. & Robertson, D. M. Insulin mediates de novo nuclear accumulation of the IGF-1/insulin hybrid receptor in corneal epithelial cells. Sci. Rep. 8(1), 4378. https://doi.org/10.1038/s41598-018-21031-7 (2018).
doi: 10.1038/s41598-018-21031-7 pubmed: 29531349 pmcid: 5847585
Nishida, T. Neurotrophic mediators and corneal wound healing. Ocular Surf. 3(4), 194–202. https://doi.org/10.1016/S1542-0124(12)70206-9 (2005).
doi: 10.1016/S1542-0124(12)70206-9
Ruiz-Lozano, R. E., Hernandez-Camarena, J. C., Loya-Garcia, D., Merayo-Lloves, J. & Rodriguez-Garcia, A. The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications: A review. Ocular Surf. 19, 224–240. https://doi.org/10.1016/j.jtos.2020.09.007 (2021).
doi: 10.1016/j.jtos.2020.09.007
Bartlett, J. D., Turner-Henson, A., Atchison, J. A., Woolley, T. W. & Pillion, D. J. Insulin administration to the eyes of normoglycemic human volunteers. J. Ocular Pharmacol. Ther. 10(4), 683–690 (1994).
doi: 10.1089/jop.1994.10.683
Bastion, M. & Ling, K.-P. Topical insulin for healing of diabetic epithelial defects? A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients. Med. J. Malay. 68(3), 209 (2013).

Auteurs

Taher K Eleiwa (TK)

Department of Ophthalmology, Benha University, Benha, Egypt. taher.eleiwa@fmed.bu.edu.eg.

Ahmed A Khater (AA)

Department of Ophthalmology, Benha University, Benha, Egypt.

Abdelrahman M Elhusseiny (AM)

Department of Ophthalmology, Kasr. Al-Ainy Hospitals, Cairo University, Cairo, Egypt.
Department of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH